518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers

التفاصيل البيبلوغرافية
العنوان: 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
المؤلفون: Banerjee, Susana, Oaknin, Ana, Sanchez-Simon, Inmaculada, Salgado, Alfonso Cortes, Patel, Sandip Pravin, Oza, Amit, Das, Mayukh, Kourtesis, Panagiotis, Ascierto, Maria Libera, Diamond, Jennifer R
المصدر: Ovarian cancer
بيانات النشر: BMJ Publishing Group Ltd
سنة النشر: 2020
نوع الوثيقة: conference object
اللغة: unknown
DOI: 10.1136/ijgc-2020-esgo.147
DOI: 10.1136/ijgc-2020-ESGO.147
الإتاحة: https://doi.org/10.1136/ijgc-2020-esgo.147Test
رقم الانضمام: edsbas.BC83C2F2
قاعدة البيانات: BASE